Highlights from the Week of 05th October 2026 - 12th October 2026

VYUHPHARMA

(FDA, Approval)

FDA approves Genentech's TECENTRIQ and TECENTRIQ HYBREZA in combination with fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA dMMR colon cancer

(FDA, Approval)

Healio obtains FDA approval of HOVILPRI to treat mucocutaneous lesions of herpes simplex virus in immunocompromised adults with no previous therapy response

(FDA, Approval)

Teva receives FDA approval of WELTRUZA for extended-release injectable suspension, to treat schizoprenia in adults

(FDA, Approval)

Pfizer's TUKYSA, in combination with trastuzumab and pertuzumab receives FDA approval for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2+ breast cancer

All logos and trademarks remain the intellectual properties of their respective owners

(Health Canada, Approval)

Health Canada gives approval to Lipocine's TLANDO capsules for testosterone replacement therapy in adults with male hypogonadism

(Health Canada, Approval)

Camurus gains Health Canada approval for OCZYESA XR subcutaneous depot for maintenance treatment in adults with acromegaly

(FDA, Breakthrough Therapy)

FDA grants two Breakthrough Therapy designations to AbbVie's ABBV-400 in CRC and NSCLC, one in combination with bevacizumab and another as a monotherapy

(Collaboration)

Vizient collaborates with Fresenius Kabi to expand supply for critical IV fluids by adding it to the Vizient Reserve Program, focusing on developing proactive solutions to manage supply challenges

All logos and trademarks remain the intellectual properties of their respective owners

(Collaboration)

Orion Pharma and Qilu collaborate to commercialize IV pembrolizumab biosimilar in Europe to treat various cancers

(Phase 3, Results)

BMS' Ph3 EXCALIBER-RRMM study, evaluating ZENBEXUS in combination with DVd and ZDd in MM, demonstrates improvement in median PFS of 42 months for ZDd and 20 months for DVd with consistent safety profile

(Phase 3, Results)

AbbVie's Ph3 trial EPCORE DLBCL-2, evaluating fixed treatment duration of epcoritamab in combination with SOC R-CHOP vs. R-CHOP alone in DLCBL, shows PFS with an IPI score of 2 to 5 and 51% reduction in disease progression risk

(Phase 3, Results)

Ph3b CROWN study of ViiV Healthcare evaluating CABENUVA achieves superior viral suppression rates compared with SOC ART in adults and adolescents with HIV-1

All logos and trademarks remain the intellectual properties of their respective owners